Holen Sie sich die Stockscreener-App
34.44
1.73%
0.375
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Sell at StockNews.com - Defense World
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! - PR Newswire
Federated Hermes Inc. Boosts Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Taking a look at what insiders are doing to gauge the Dyne Therapeutics Inc (DYN)’s direction - Knox Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - AccessWire
Trading Day Review: Dyne Therapeutics Inc (DYN) Gains Momentum, Closing at 33.07 - The Dwinnex
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by TD Asset Management Inc - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by TD Asset Management Inc - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - AccessWire
Dyne Therapeutics (NASDAQ:DYN) Lowered to “Sell” at StockNews.com - Defense World
StockNews.com Lowers Dyne Therapeutics (NASDAQ:DYN) to Sell - MarketBeat
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf - The Bakersfield Californian
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Check Out Dyne Therapeutics Inc (DYN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Bank of New York Mellon Corp - Defense World
Research Analysts’ Recent Ratings Changes for Dyne Therapeutics (DYN) - Defense World
Dyne therapeutics director sells over $55,000 in company stock - Investing.com
Dyne therapeutics director sells over $55,000 in company stock By Investing.com - Investing.com Canada
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN) - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Reach Out - AccessWire
Dyne Therapeutics Inc (DYN) stock analysis: A simple moving average approach - US Post News
Investors In Dyne Therapeutics, Inc. Are Invited To Join An Investigation For Possible Securities Related Infractions - StockTitan
Financial Health Report: Dyne Therapeutics Inc (DYN)’s Ratios Tell a Tale - The Dwinnex
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.4% - Defense World
Candriam S.C.A. Reduces Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Candriam S.C.A. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.4% - MarketBeat
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Dyne Therapeutics CEO, President & Director Acquires 640% More Stock - Simply Wall St
John Cox Acquires 32,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc.(DYN) and Encourages Stockholders to Learn More About the Investigation - AccessWire
(DYN) INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
The Escalator: MM+M, Dyne Therapeutics, EyePoint Pharmaceuticals and more - MM+M Online
Petri Dish: Dyne’s Duchenne data; Foghorn hires BMS leader - The Business Journals
Dyne Therapeutics (NASDAQ:DYN) Given “Buy” Rating at HC Wainwright - Defense World
Dyne therapeutics director sells over $1.4m in company stock - Investing.com
Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO Buys $1,057,280.00 in Stock - MarketBeat
Dyne therapeutics director sells over $1.4m in company stock By Investing.com - Investing.com Canada
Dyne therapeutics CEO buys over $1m in company stock By Investing.com - Investing.com Australia
Dyne therapeutics CEO buys over $1m in company stock By Investing.com - Investing.com Canada
Dyne therapeutics CEO buys over $1m in company stock - Investing.com
Dyne therapeutics CEO buys over $1m in company stock - Investing.com India
Dyne therapeutics CEO buys over $1m in company stock By Investing.com - Investing.com UK
Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street (DYN) - Seeking Alpha
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Dyne therapeutics director sells over $1.4m in company stock By Investing.com - Investing.com UK
Dyne Therapeutics (NASDAQ:DYN) Shares Up 7.9% - MarketBeat
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation - AccessWire
HC Wainwright Reiterates "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN) - MarketBeat
Biotech Crashes, Executives Depart Despite 'Unprecedented' Results - Investor's Business Daily
Dyne stock tumbles 31% amid drug updates, management changes - MSN
Dyne Therapeutics’ (DYN) “Outperform” Rating Reaffirmed at Oppenheimer - Defense World
Dyne Therapeutics reshuffles leadership team - Investing.com
Dyne stumbles on toxicity, leadership concerns - BioCentury
The Attractiveness of Investing In Dyne Therapeutics Inc (DYN) is Growing - Knox Daily
Dyne Therapeutics (NASDAQ:DYN) Rating Reiterated by Oppenheimer - MarketBeat
Dyne stock tumbles 31% amid drug updates, management changes (NASDAQ:DYN) - Seeking Alpha
Three in and three out on damaging day for Dyne - The Pharma Letter
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $46.09 - MarketBeat
Dyne Therapeutics maintains steady target with positive data - Investing.com
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy - Yahoo Finance
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building - MSN
3 execs resign as Dyne posts mixed data for DMD candidate - Fierce Biotech
Dyne Therapeutics reshuffles leadership team By Investing.com - Investing.com Canada
Dyne Therapeutics reshuffles leadership team By Investing.com - Investing.com Australia
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - MSN
Dyne Therapeutics slumps on safety concerns over drug trial, management changes - XM
There is no way Dyne Therapeutics Inc (DYN) can keep these numbers up - SETE News
Long Term Trading Analysis for (DYN) - Stock Traders Daily
Dyne Therapeutics announces C-level executive changes - MSN
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Dyne Therapeutics: Executive Shifts and Promising Clinical Trials - TipRanks
1.19%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):